Zentiva Group announced a transfer agreement with Sanofi to acquire production facilities in Ankleshwar, India. With this acquisition, Zentiva is expanding its operations and capabilities of its manufacturing network and will be ready to ensure the continuity of supply of quality medicines to even more patients.
“The expansion of Zentiva’s wholly owned manufacturing network is a key factor in our future success and will ensure even greater security of supply not only for European citizens. It will enable us to realize further innovations to achieve our goals of optimizing operations, increasing productivity and accelerating growth,”
said Nick Haggar, Zentiva CEO.
In response to the growing demand for quality and affordable medicines, this acquisition confirms Zentiva’s commitment to providing maximum support to pharmacists, healthcare professionals and decision-makers in improving access to healthcare.
In order to maximize production capacity, Zentiva has expanded its network earlier this year through the acquisition of Solacium in Romania and Creo in the United Kingdom and has also invested millions of euros in its production facilities in Prague and Bucharest.
The transaction is subject to regulatory, shareholder approval, and certain terms and conditions under the Plant Transfer Agreement.